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Abstract
Background Endoscopic papillary large balloon dilatation
(EPLBD) after endoscopic sphincterotomy (EST) has
recently become widely used for common bile duct (CBD)
stone removal, but many clinicians remain concerned about
post-procedural pancreatitis with increasing the balloon size
to over 15 mm.
Aims We aimed to evaluate the safety and efficacy of
EPLBD with a relatively large balloon (15–20 mm) after
EST and to evaluate the factors related to post-EPLBD
pancreatitis.
Methods A retrospective review was undertaken of the
endoscopic database of 101 patients with CBD stones who
underwent EPLBD using a larger balloon size of over
15 mm (15–20 mm). Clinical parameters, endoscopic data,
and outcomes were analyzed.
Results The mean age of the subjects was 69 years. All
patients had a dilated CBD of over 11 mm (mean =
22.6 mm). The mean size of balloon used in EPLBD was
17.1 ± 1.9 mm (range 15–20 mm). Mechanical lithotripsy
was required in seven patients (6.9%). The rate of complete
stone removal in the first session was 92.1%. Post-proce-
dural pancreatitis developed in five cases (5.4%), but none
were graded as severe. The smaller dilatation of the CBD,
longer cannulation time, and longer time for stone removal
were associated with post-procedural pancreatitis, but larger
size of balloon did not affect the development of post-
EPLBD pancreatitis.
Conclusions EPLBD with a large balloon of over 15 mm
with EST is an effective and safe procedure with a very low
probability of severe post-procedural pancreatitis. Post-
EPLBD pancreatitis was not associated with larger balloon
size, but was associated with longer procedure time and
smaller dilatation of the CBD.
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Introduction
Endoscopic papillary balloon dilation (EPBD) using a
small-diameter balloon catheter (5–10 mm) was introduced
in 1982 as an alternative to endoscopic sphincterotomy
(EST), and is considered to have advantages in preserving
the sphincter function and decreasing bleeding complica-
tions of EST [1, 2]. So, EPBD has frequently been per-
formed, and many trials have compared the efficacy and
safety of EPBD with EST for the removal of bile duct stones
[3–5]. However, EPBD has been reported to have a higher
risk of pancreatitis than EST in some studies, and there are
still debates over the use of EPBD and the risk of developing
pancreatitis following the procedure [6–8]. Moreover, for
the extraction of large bile duct stones, both EST and EPBD
have limitations because of the frequent additional need for
mechanical lithotripsy (ML). Therefore, as an alternative to
conventional EPBD using a small balloon of less than
10 mm in size, the technique of endoscopic papillary large
balloon dilatation (EPLBD) using a balloon larger than
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12 mm after mid-incision EST was introduced for the
removal of large common bile duct (CBD) stones [9].
Despite concerns about serious complications such as severe
pancreatitis and bile duct perforations caused by large bal-
loon inflation, recent data has suggested that EPLBD is an
effective procedure that does not cause complications if
performed under strictly established guidelines [10–14].
However, many clinicians remain concerned about post-
procedural pancreatitis with increasing balloon size, espe-
cially those over 15 mm. The aims of this study were to
investigate whether increasing the size of the inflating bal-
loon is a risk factor for pancreatitis, to evaluate the efficacy
and safety of EPLBD with a relatively large balloon
(15–20 mm) after EST, and to evaluate the clinical factors
related to post-EPLBD pancreatitis.
Methods
Patients
The study participants included 101 consecutive patients
with CBD stones who underwent EST and EPLBD using a
balloon larger than 15 mm at Gangnam Severance Hospital
from November 2004 to November 2008. The medical
records and endoscopic database of the patients were
reviewed retrospectively. The criteria for selecting patients
were a sufficiently dilated CBD ([10 mm) and a large or
multiple bile duct stones (C13 mm or C3 stones). Exclusion
criteria included CBD with stricture and CBD with no
dilatation (B10 mm). We routinely applied the EPLBD
procedure during the study period on most of the patients
who met the above criteria. All patients were fully informed
about the methods and possible complications of the pro-
cedure and were recruited after written consent had been
obtained.
Endoscopic Procedure
All endoscopic procedures were performed under conscious
sedation with intravenous midazolam, meperidine hydro-
chloride, and/or propofol. Protease inhibitors, which might
affect the incidence of procedure-associated pancreatitis,
were not administered routinely either before or after
endoscopic retrograde cholangiopancreatography (ERCP).
Two expert endoscopists performed the ERCP using
a standard duodenoscope (JF-240, TJF-240; Olympus
Optical Co. Ltd., Tokyo, Japan). Contrast medium (60%
amidotrizoate sodium meglumine, Schering, Osaka, Japan)
was used at a 1:1 dilution. A 0.035 Fr catheter (ERCP-Kat-
heter; MTW Endoskopie, Wesel, Germany) and a guide-
wire (0.035-inch, Boston Scientific Corporation, Natick,
MA, USA) were used for diagnostic cholangiograms.
Mid-incision EST with pull-type sphincterotome (Papillo-
tome, MTW Endoskopie, Wesel, Germany) was performed
and extended beyond the top of the transverse fold or the
superior margin of the papilla bulge. Pre-cut sphincterotomy
was performed for the cannulation of inaccessible bile ducts.
A generator with an automatically controlled cut-out system
(Endocut mode, ICC200, ERBE Elektromedizin GmbH,
Tubingen, Germany) was used for EST. A 5 Fr over-the-
guidewire type of hydrostatic balloon catheter (controlled
radial expansion [CRE] dilation balloon; esophageal/pyloric;
maximum diameter 15, 18, or 20 mm; length 5 cm; Micro-
vasive, Boston Scientific Corporation) was inserted over the
guidewire and positioned across the main duodenal papilla.
The maximum diameter of balloon was chosen during ERCP
among the sizes 15, 18, or 20 mm, not exceeding 2–3 mm
over the dilatation of the distal CBD.
The balloon was then gradually inflated to 15–20 mm
with diluted contrast using an inflation device (Indeflator;
Abbott, Santa Clara, CA, USA). The sphincter was con-
sidered to be adequately dilated if the waist in the balloon
had disappeared completely on fluoroscopic examination,
and then the fully dilated balloon was maintained for
30–60 s. If the waist of the balloon could not be resolved
even with near-maximal pressure (6–8 atm) or if longitu-
dinally extensive narrowing of the balloon was recognized,
the pressure of inflation was not increased further to avoid
perforation. The bile duct stones were extracted using a
Dormia basket (Web extraction basket; Wilson-Cook
Medical Inc., Winston-Salem, NC, USA) and/or a retrieval
balloon catheter (Boston Scientific Corporation) (Fig. 1).
A mechanical lithotripter (Lithotriptoren; MTW Endo-
skopie) was used to crush the stones when extraction could
not be achieved by basket or retrieval balloon even after
EPLBD with EST. If remnant stones were suspected, a
second session of ERCP with or without repeated EPLBD
was performed.
Measurement of Outcomes
For the close monitoring and early handling of possible
complications, abdominal X-rays and blood sample anal-
yses for complete blood count, liver-function tests, con-
centration of serum amylase and lipase, and coagulation
profiles were routinely performed on the day of the ERCP
procedure and on the following day in all patients. The size
and number of bile duct stones and the diameter of the
CBD was assessed using an initial diagnostic cholangio-
gram by comparing the diameter of the stone and CBD
with the tip of the endoscope, with correction for magni-
fication of the external diameter of the distal end of the
duodenoscope (13.5 mm). The angle of the distal CBD
with the horizontal plane was measured using the angle
between the inflated balloon and the horizontal plane of the
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vertebra (Fig. 2), and was also analyzed for possible
association with complications. The technical success of
the procedure was defined as complete removal of all CBD
stones. The number of sessions required for complete stone
removal, the frequency of use of ML, and associated
complications such as pancreatitis, hyperamylasemia,
bleeding, and perforation were classified and graded
according to the consensus guidelines [15]. The severity of
pancreatitis was graded according to Ueno’s modification
of the Cotton criteria: minimal (complaint of abdominal
pain persisting 12–24 h with at least threefold elevation of
serum amylase concentration); mild (clinical pancreatitis
with at least threefold elevation of serum amylase con-
centration, requiring 1–3 days of treatment); moderate
(requiring 4–10 days of treatment); and severe (requiring
more than 10 days of medication, or percutaneous or sur-
gical intervention) [16].
Data Management and Statistical Analysis
Statistical analyses were performed using statistical soft-
ware (SPSS 12.0 for Windows; SPSS Inc., Chicago, IL,
USA). Quantitative data are presented as the mean ±
standard deviation (SD). The Mann–Whitney test, Chi-
square test, and independent sample t-test were used to
compare variables between the complication group and the
no-complication group, and logistic regression analysis
was used for the independency test of the variables. A
P-value \0.05 was considered to be significant.
Results
The baseline characteristics and demographic data are
shown in Table 1.
Fig. 1a–h Endoscopic papillary large balloon dilatation (EPLBD)
procedure. a Cholangiogram shows a large dilated common bile duct
(CBD) and multiple bile duct stones. b Endoscopic sphincterotomy is
performed. c, d Papillary dilation with a 20-mm large balloon.
e–g Large bile duct stones were removed without crushing, by balloon
retrieval and Dormia basket. h Large biliary orifice after the
procedure
Fig. 2 The angle of the distal common bile duct (CBD) with the
horizontal plane. The angle of the distal CBD was measured as the
angle between the inflated balloon at the ampulla and the horizontal
plane of the vertebra (black lines)
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In all patients, the EPLBD with EST procedures were
successful, and complete retrievals of bile duct stones were
achieved. The majority of patients had multiple bile duct
stones, and all patients had a dilated CBD [11 mm. Suc-
cessful stone removal in the initial session of ERCP with
EPLBD was accomplished in 93 patients (92.1%), and ML
was required in seven patients (6.9%). The size of the
balloon used in EPLBD was 17.1 ± 1.9 mm (range
15–20 mm). The characteristics of choledocholithiasis and
the results of stone removal with EPLBD are summarized
in Table 2.
With respect to complications, there were five cases
(5.0%) of post-procedural pancreatitis (three minimal, one
mild, and one moderate), two cases (2.0%) of bleeding and
intramural dissection, and one case (1%) of perforation
(Table 3). Post-ERCP hyperamylasemia, defined as the
elevation of serum amylase concentration to threefold
greater than the normal upper limit without clinical pan-
creatitis, was noted in three patients (3.0%). There was no
patient who received pancreatic stent to prevent pancrea-
titis after EPLBD; however, there were no cases of severe
pancreatitis related to EPLBD. Two cases of bleeding were
controlled with a combination of epinephrine injection,
electrical coagulation, and balloon tamponade, and one
case of microperforation was treated by conservative
management with intravenous antibiotics and NPO.
When clinical and endoscopic parameters were com-
pared according to the development of post-procedural
pancreatitis, no significant associations were found for age,
body mass index, gender, size or the number of CBD
stones, periampullary diverticulum, usage of mechanical
lithotripsy, usage of pre-cut EST, incomplete inflation
(notching during inflation), previous history of pancreatitis,
cholangitis and gastric surgery, or the presence of jaundice
and other comorbid medical conditions. The angle of the
distal CBD with the horizontal plane and the size of the
balloon used in EPLBD also did not affect the development
of post-procedural pancreatitis. However, we did find that
smaller dilatation of the CBD, longer cannulation time, and
longer stone removal time were significantly associated
with the development of post-procedural pancreatitis, and
these three factors were also shown to independently affect
the risk of pancreatitis in the logistic regression analysis
(Table 4).
Discussion
EPBD with a small balloon of size \10 mm might have
advantages on preserving sphincter function [17–19], but
there have been serious issues concerning the risk of pan-
creatitis in EPBD following two cases of mortality due to
severe pancreatitis in middle-aged patients during a ran-
domized trial in the United States [6]. However, EPLBD
introduced a different concept, results in the rupture of the
orifice and permanent loss of the sphincter, and simplifies
the retrieval of a large stone [9]. Several studies on EPLBD
have demonstrated a relatively high technical success rate,
ranging from 74 to 99% without ML for the removal of
large bile duct stones, which are similar to our data (93.1%
Table 1 Demographic data and baseline characteristics of the
patients
Age (years) 69.1 ± 11.7 (range 36–92)
Gender (M:F) 40:61
Body mass index (BMI) 22.7 ± 3.2 (range 17.8–36.2)
Prior history of acute pancreatitis 10 (10.0%)
Previous gastric surgery
Billroth I 2 (2.0%)
Billroth II 3 (3.0%)
Hyperbilirubinemia
(total bilirubin [ 1.3 mg/dL)
41 (40.6%)
Periampullary diverticulum 12 (11.9%)
Diabetes mellitus 5 (5.0%)
Liver cirrhosis 2 (2.0%)
Table 2 Characteristics of choledocholithiasis and the results of
stone clearance with EPLBD
Number of CBD stones
Single 39 (38.6%)
Multiple 62 (61.4%)
Mean size of CBD stone (mm) 21.8 ± 8.5 (range 7–52)
CBD diameter (mm) 22.6 ± 5.7 (range 11–45)
Size of balloon (mm) 17.1 ± 1.9 (range 15–20)
Overall success in stone removal 101 (100%)
Sessions required for complete stone removal
Single session 93 (92.1%)
Two sessions 8 (7.9%)
Mechanical lithotripsy 7 (6.9%)
EPLBD endoscopic papillary large balloon dilatation, CBD common
bile duct
Table 3 Complications associated with EPLBD




Bleeding, mild 2 (2.0%)
Intramural dissection 2 (2%)
Microperforation 1 (1.0%)
EPLBD endoscopic papillary large balloon dilatation, CBD common
bile duct
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without ML), and relatively low rates of pancreatitis
[9–14]. Because EPLBD shares a similar method of bal-
looning to that of EPBD, there are still some concerns
about the risk of pancreatitis.
The mechanisms underlying post-EPBD or post-EPLBD
pancreatitis seem to be multifactorial, and suggested
mechanisms were that (1) the direct physical compression
effect of the balloon on the papilla, pancreatic duct orifice,
or parenchyme may induce peripapillary edema or spasm
of the sphincter, or that (2) repeated bile duct cannulation
or transpapillary manipulation due to difficulty in cannu-
lation or stone extraction may induce edema or spasm and,
in turn, obstruct the flow of pancreatic juice and, eventu-
ally, induce pancreatitis [4, 20–22]. However, it is unclear
whether the major factor in the induction of pancreatitis is
the ballooning itself (and is, therefore, related to the bal-
loon size) or to problems in selective cannulation and
transpapillary manipulation. So, many clinicians still have
concerns and hesitate to use larger balloons over 15 mm in
size. We analyzed the cases involving especially large
balloons (C15 mm), to investigate whether or not the
increase in balloon size is a possible cause of pancreatitis.
In our results, the frequency of pancreatitis after EPLBD
using balloons over 15 mm in size was only 5% (with no
cases of severe pancreatitis), and was not higher than the
findings of most previous EPLBD series [9–14] using
smaller balloons (12–15 mm) than our study. Our data
support the proposal that increased balloon size and direct
physical compression effects by the balloon itself are not a
major cause of post-procedural pancreatitis.
To date, there have been a few studies on the risk factors
of post-EPBD pancreatitis. Bergman et al. [22] found no
predictive factors for post-EPBD hyperamylasemia or
pancreatitis in their multivariate analysis, whereas Sugiy-
ama et al. [23, 24] reported four independent risk factors
for hyperamylasemia: age B60 years, previous pancreati-
tis, bile duct diameter B9 mm, and difficult bile duct
cannulation. The present study also showed three
independent risk factors predictive of pancreatitis after
EPLBD: smaller degree of CBD dilatation, prolonged time
required for cannulation, and longer time of stone removal.
In patients with smaller degrees of CBD dilatation,
EPLBD is not a suitable procedure because of the risk for
perforation and pancreatitis as well. The finding of our
study that a lesser degree of CBD dilatation is a risk factor
for post-EPLBD pancreatitis is in good agreement with
many authors who speculate that an appropriately dilated
CBD might be very important when EPLBD is applied.
Our data also showed an independently increased risk
for pancreatitis in cases with prolonged time required for
cannulation and a longer time for stone removal. These
findings suggest that the most important factor influencing
post-EPLBD pancreatitis might be the papillary and
transpapillary manipulation times. When applied to an
appropriately dilated CBD, sufficient dilation of the papilla
using a large-diameter balloon might both facilitate easier
and faster stone extraction and reduce trauma to papilla
during stone extraction, thus, having a beneficial effect on
the outcome. In our present study, the application of ML
did not affect the risk of pancreatitis, whereas the total time
for stone removal independently affected the occurrence of
pancreatitis. Based on these findings, the quicker stone
extraction by sufficiently large dilation of the papilla and
an earlier decision to use ML (if needed) in cases of dif-
ficult stone retrieval might be beneficial.
The history of previous pancreatitis and younger age
(B60 years) have also been reported as risk factors for
post-EPBD hyperamylasemia [23, 24], but they were not
significant in our data. These factors might have been
underestimated in the present study because the number of
patients with history of pancreatitis and the number of
younger patients were relatively small.
The main limitation of our study was its retrospective
nature and non-comparative one-arm treatment analysis in
single center. In addition, the study included many older
patients, whose risk of pancreatitis might be small.
Table 4 Clinical and endoscopic parameters associated with post-EPLBD pancreatitis
No post-EPLBD
pancreatitis (n = 96)
Patients with post-EPLBD
pancreatitis (n = 5)
P-value P-value by
logistic regression
Age (years) 69.6 ± 11.5 62.3 ± 13.1 0.11
History of prior pancreatitis 9/96 (9.4%) 1/5 (20.0%) 0.41
Mechanical lithotripsy 7/96 (7.3%) 0/5 (0%) 1.00
Pre-cut EST 6/96 (6.3%) 0/5 (0%) 1.00
Size of EPLBD balloon (mm) 17.1 ± 1.9 17.0 ± 2.4 0.94
Angle of the distal CBD with the horizontal plane () 89.5 ± 16.3 92.5 ± 12.5 0.68
CBD diameter (mm) 23.0 ± 5.4 17.6 ± 6.7 0.02 0.05
Cannulation time (min) 4.5 ± 2.8 10.4 ± 6.1 0.01 0.01
Stone removal time (min) 17.4 ± 13.4 30.0 ± 3.5 0.01 0.04
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In conclusion, the application of a larger balloon over
15 mm in size by EPLBD is an effective and safe proce-
dure with respect to pancreatitis in patients with a suffi-
ciently dilated CBD. Post-EPLBD pancreatitis is associated
with longer procedure time, including cannulation time and
stone removal time, rather than larger balloon size. Finally,
to reduce the risk of post-EPLBD pancreatitis, the selection
of patients with sufficient CBD dilatation and the avoid-
ance of excessive papillary manipulation appears to be
important.
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